RT Journal Article
SR Electronic
T1 Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2020-002669
DO 10.1136/ejhpharm-2020-002669
A1 Raquel Moreno Diaz
A1 Miguel Angel Amor García
A1 Francisco Javier Teigell Muñoz
A1 Leonardo Ernesto Saldaña Perez
A1 María Mateos Gonzalez
A1 Jose Antonio Melero Bermejo
A1 Alberto López Hernández
A1 Laura Reyes Marquez
A1 Maria Teresa De Guzman García-Monge
A1 Jose Luis Perez Quero
A1 Marcela Patricia Homez Guzman
YR 2021
UL http://ejhp.bmj.com/content/early/2021/04/18/ejhpharm-2020-002669.abstract
AB Introduction While there are no pharmacological treatments with proven efficacy for coronavirus disease 2019 (COVID-19), tocilizumab has emerged as a candidate therapy. Some aspects of this therapy are still unknown, including the optimal timing of administration.Objective This observational study aimed to compare the 90-day mortality in two cohorts of patients when the drug was administered within the first 10 days from onset of symptoms or after day 11.Methods Patients hospitalised with severe COVID-19 pneumonia who had received tocilizumab were divided into two groups according to when the medication was administered. The primary outcome was 90-day mortality. Secondary outcomes were 30-day mortality, clinical improvement on a 6-item scale by day 6, biomarker improvement by day 6, radiological image improvement by day 10 and SaO2 quotient by day 6. The results in the two groups were compared. Additionally, adverse events relating to tocilizumab were recorded.Results A total of 112 patients were analysed. Both groups were epidemiologically comparable. The results obtained in the primary efficacy variable of the study (90-day mortality) showed a statistically significant difference in the subgroups according to the time of administration of tocilizumab (18.6% vs 5.0%, p=0.048). There was clinical improvement in 24.1% of patients at 6 days, with similar behaviour in both subgroups. No statistically significant differences were found in the percentage of patients who achieved radiological improvement at 10 days or in the other inflammatory parameters, with the exception of significant reductions in lactate dehydrogenase and C-reactive protein. Administration of tocilizumab was not associated with relevant adverse events.Conclusion To our knowledge, this is the first report of data regarding the timing of administration of tocilizumab in patients with COVID-19 pneumonia. A strategy involving tocilizumab administration after 10 days from onset of symptoms may decrease mortality. Further randomised controlled trials are needed to confirm this emerging hypothesis.All data relevant to the study are included in the article or uploaded as supplementary information.